Recent Trends
'n Survival Off
Cancer Patients
1960 - 1971||
U S DEPARTMENT OF
HEALTH, EDUCATION AND WELFARE
Public Health Service
National Institutes of Health


Msdical Library
X5
C- -
2320
2
A supplement to End Results in Cancer, Report No. 4
Prepared for END RESULTS GROUP
by END RESULTS SECTION, BIOMETRY BRANCH
NATIONAL CANCER INSTITUTE
Edited by: Lillian M. Axtell, M.A.; Max H. Myers, Ph.D.
With the assistance of: The End Results Section Staff
DHEW Publication No. (NIH) 75-767
U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service • National Institutes of Health
National Cancer Institute, Bethesda, Maryland 20014
1974
Medical library
/*C
22 º
, & S (/
//7%
END RESULTS GROUP PARTICIPANTS
CENTRAL REGISTRIES
California Tumor Registry Connecticut Tumor Registry Massachusetts Cancer Registry
Berkeley, California Hartford, Connecticut Boston, Massachusetts
*-
INDIVIDUAL HOSPITAL REGISTRIES
Charity Hospital of Louisiana University of Chicago Clinics
New Orleans, Louisiana Chicago, Illinois
Indiana University Medical Center University of Michigan Hospital
Indianapolis, Indiana Ann Arbor, Michigan
State University of lowa Hospital University of Virginia Hospital
lowa City, Iowa Charlottesville, Virginia
The End Results Evaluation Program is in part supported by contracts
with the National Cancer Institute, Public Health Service.
W ºf / \p
**, *, *
*ABLE OF contents
Page
INTRODUCTION -----------------------------------------------------------------. 2
CANCER OF BUCCAL CAVITY AND PHARYNX 8
Lip ----------------------------------------------------
Tongue ------------------------------------------------- 9
Salivary gland ------------------------------------------- 10
Floor of mouth ------------------------------------------- 11
Other mouth --------------------------------------------- 12
Total Pharynx -------------------------------------------- 13
Mesopharynx -------------------------------------------- 14
Nasopharynx -------------------------------------------- 15
HyPoPharynx -------------------------------------------- 16
CANCER OF DIGESTIVE SYSTEM
Esophagus ---------------------------------------------- 18
Stomach ----------------------------------------------- 19
Total colon ---------------------------------------------- 20
Ascending Colon, Caecum, and appendix –––––––––––––––––––––––– 21
Transverse colon ----------------------------------------- 22
Descending colon ----------------------------------------- 23
Sigmoid colon -------------------------------------- * - - mººs º- - 24
Total rectum -------------------------------------------- 25
Rectum ------------------------------------------------ 26
Rectosigmoid -------------------------------------------- 27
ºver -------------------------------------------------- 28
Gallbladder and ducts –––––––––––––––––––––––––––––––––––––– 29
Pancreas ----------------------------------------------- 30
CANCER OF RESPIRATORY SYSTEM
Nose, nasal cavities, and middle ear --------------------------- 32
Hayſ' ------------------------------------------------- 33
Lung and bronchus ---------------------------------------- 34
CANCER OF FEMALE REPRODUCTIVE SYSTEM
Female breast ------------------------------------------- 36
Cervix uter --------------------------------------------- 37
Corpus uter --------------------------------------------- 38
9%ary -------------------------------------------------- 39
Vulva -------------------------------------------------- 40
Vagina ------------------------------------------------- 41
CANCER OF MALE GENITAL ORGANS
Frºstate ------------------------------------------------ 44
"**** -------------------------------------------------- 45
* -------------------------------------------------- 46
CANCER OF URINARY ORGANS
Kidney ------------------------------------------------- 48
Bladder ------------------------------------------------ 49
CANCER OF OTHER SITES
Melanoma of skin ----------------------------------------- 52
F)* --------------------------------------------------- 53
Brain and cranial meninges --------------------------------- 54
Thyroid gland -------------------------------------------- 55
* -------------------------------------------------- 56
LYMPHOMA
LEUKEMIA
REFERENCE
Reticulum cell sarcoma ––––––––––––––––––––––––––––––––––––
Lymphosarcoma ------------------------------------------
Hodgkin's disease ––––––––––––––––––––––––––––––––––––––––
Other forms of lymphoma -----------------------------------
Multiple myeloma ––––––––––––––––––––––––––––––––––––– — — — —
Total acute leukemia -------------------------- ------------
Acute lymphocytic leukemia ---------------------------------
Acute myelocytic leukemia ----------------------------------
Monocytic leukemia –––––––––––––––––––––––––––––––––––––––
Total chronic leukemia –––––––––––––––––––––––––––––––––––––
Chronic lymphocytic leukemia --------------------------------
Chronic myelocytic leukemia ---------------------------------
RODUCTION
ſae


This report supplements the data presented by the End Re-
sults Group in End Results in Cancer, Report No. 4 (1), an
analysis of survival for white cancer patients diagnosed 1940
through 1969. In the earlier report 5-year survival rates for
patients diagnosed 1965-69 were not available since the pa-
tients could be followed only into 1970. For this report follow-
up information was available into 1972, thus permitting the
actuarial calculation of 5-year survival rates for patients diag-
nosed during 1965-69 and provisional 1-year survival rates
for patients diagnosed during 1970-71. In addition to the
provisional rates for 1970-71, 1-year, 3-year and 5-year ob-
Served and relative survival rates for 1960-64 and 1965-69
have been recalculated using the latest survival information
for the 48 forms of cancer included in the previous report ".
The relative survival rate is defined as the ratio of the
observed rate to the rate expected in a group of people in
the general population similar to the patient population with
respect to race, sex, age and calendar period of observation.
It provides for an adjustment for “normal” mortality which
makes possible meaningful comparisons of survival experi-
ences that differ with respect to demographic characteristics
and calendar time.
* For some forms of cancer, more detailed analyses reflecting variation
in survival by histologic type are under way.
DESCRIPTION OF DATA SUMMARY OBSERVATIONS FOR PATIENTS
WITH SOLID TUMCRS
The data are based on the experience of
cancer patients treated in more than 100
hospitals participating in the End Results
Evaluation Program sponsored by the Na-
tional Cancer Institute. Included are all the
hospitals in the State of Connecticut, about
one-third of the hospitals in the State of
California, a group of hospitals in the Boston
metropolitan area and 6 large university
hospitals in various parts of the United
States. They represent a broad spectrum of
hospitals and provide a reasonable basis for
assessing the trends in the management of
cancer patients in the United States.
The stage of disease, i.e., localized, re-
gional and distant, is based on all informa-
tion which was available during the first
course of treatment. The classification of
treatment is limited to the first course of
tumor-directed therapy initiated within four
months of diagnosis. ...
Both reports exclude patients with “car-
cinoma in situ'', non-melanotic skin can-
cers and those patients with cancers diag-
nosed at autopsy.
Trends in survival over the past 20 years
have varied—for some sites there has been
continuous improvement; for other sites
there has been little or no improvement
since the 1950's. Table 1 shows the trend
in prognosis in terms of 5-year relative sur-
vival rates for sites for which there has been
noticeable improvement since the 1950's.
This table also includes the percent of can-
cers diagnosed as localized and the per-
cent of the cases not definitively treated
within four months of diagnosis. This group
of sites represents approximately 36 per-
cent of all cancer cases.
Survival for men with cancer of the
larynx showed considerable improvement
between 1950-59 and 1965-69 for patients
with localized disease as well as for all
stages of disease. The 5-year survival rate
increased from 56 to 62 percent for all
stages and from 74 to 80 percent for lo-
calized. For women there were only small
increases in survival.
For all women with breast cancer there

was an increase in 5-year survival rates
from 60 percent during 1950-59 to 64 per-
cent during 1965-69. However, there was
no increase in survival for women with lo-
calized breast cancer. The increase in sur-
vival for all patients combined reflects the
increase in the proportion of women diag-
nosed with localized disease, an increase
from 42 to 47 percent.
There was very little change in overall
survival for lung cancer patients although
there was marked improvement for those
with localized disease. Unfortunately, a re-
duction in the percentage of patients re-
ceiving no cancer directed therapy within
4 months of diagnosis has not resulted in
improved overall survival results for lung
Carl Cer. -
For patients with cancers of the prostate,
testis, kidney, bladder, brain, thyroid, and
with melanomas of the skin there were.
marked improvements in survival even
among localized cases.
SUMMARY OBSERVATIONS FOR PATIENTS WITH
LYMPHOMAS OR LEUKEMIAS
Trends in 1-year and 5-year survival rates
for patients with lymphomas or leukemia
are shown in Table 2. There has been little
improvement in survival for reticulum cell
sarcoma and lymphosarcoma patients be-
tween the 1950's and late 1960's. The pro-
visional 1-year rate for 1970-71 suggesis
that prognosis for patients diagnosed dur-
ing the early 1970's will be more favorable
than for those diagnosed during the 1960's.
For Hodgkin's disease patients, there has
been an impressive improvement in Survival
during the late 1960's. Among men with
Hodgkin's disease there was an increase in
5-year survival from 31 percent during the
1950's to 38 percent during 1960-64 and
52 percent during 1965-69. A similar sur-
vival pattern was observed for women. The
1-year provisional rates for Hodgkin's dis-
ease show promise for continued improve-
ment for the 1970's.
The trend in survival for children under
15 years of age with acute leukemia has
been very impressive. Whereas in the 1950's
only 1 in 4 children survived one year with
this disease, in the late 1960's 6 out of 10
survived one year and provisional results
for 1970-71 suggest that the upward trend
is continuing. Results are somewhat more
favorable for children with acute lymphocy-
tic leukemia for which the provisional 1-
year survival rate for children diagnosed
during 1970-71 is 80 percent.
We have only attempted to summarize
briefly the cancer survival results that are
presented in more detail in the tables that
follow. These tables provide 5-year survival
for patients diagnosed during 1965-69 and
1-year provisional results for those diag-
nosed during 1970-71 which were not avail.
able previously. The tables show for each
form of cancer stage distributions (localized,
regional, distant) by sex and calendar period
of diagnosis; treatment distributions (sur-
gery, radiation, chemotherapy, etc.) by Sex
and calendar period of diagnosis and sur-
vival (1-, 3- and 5-year observed and rela-
tive rates) by sex, calendar period of diag-
nosis, and stage.
TABLE 1. Solid tumor sites showing improvements in 5–year relative
survival rates: 1950 – 1969.
Percen Percent not 5—year rate
Localized Treated All stages | Localized
M F M F M F M F
Larynx 1950–59% 60 59 11 13 56 57 74 71
1960–64 60 57 7 8 54 52 72 67
1965–69 61 57 5 4 62 59 80 73
Lung 1950–59* 18 19 39 42 7 11 24 40
- 1960–64 19 27 19 28 8 12 27 42
1965–69 18 25 17 22 8 12 29 48
Breast 1950–59% 42 5 60 83
1960–64 45 4 62 84
1965–69 47 3 64 34
Prostate 1950–59% 52 10 47 61
1960–64 60 7 52 65
1965–69 63 6 56 68
Testis 1950–59% 58 4 61 82
1960–64 60 1 65 84
1965–69 53 1 67 89
Kidney 1950–59% 41 46 25 21 32 36 59 59
-: 1960–64. 44 50 19 15 35 38 || 62 60
1965–69 44 49 13 12 39 44 66 69
Bladder 1950–59% 71 67 10 10 55 53 68 69
1960–64 78 76 7 7 57 56 67 69
1965–69 81 76 5 7 61 60 70 76
Melanoma of skin 1950–59° 56 65 10 7 51 60 70 79
1960–64 61 75 6 3 52 70 74 82
1965–69 66 77 4 3 61 73 75 85
Brain 1950–59% 70 72 30 28 22 28 24 30
1960–64 83 83 18 22 21 27 22 30
1965–69 87 85 14 15 27 32 28 34
Thyroid 1950–59* 38 54 9 6 70 83 88 95
1960–64 38 54 6 4 77 86 92 96
1965–69 42 57 4 4 78 87 99 97

*Source: End Results in Cancer, Report No. 4

TABLE 2. 1–year, 5–year Relative Survival Rates for
!:
}}
Lymphoma and Leukemia Patients: 1950 – 1971
Male Female
1950– | 1960— | 1965— | 1970— | 1950— | 1960— | 1965– | 1970–
59* 64 69 71+ 59* 64 69 71+
Reticulum Cell 1–year 35 37 38 41 34 32 43 52
Sarcoma 5—year 16 17 16 * =º- 17 14 20 †-º
Lymphosarcoma 1—year 54 61 59 65 56 57 63 69
5—year 26 32 32 gº 30 30 32 ---,
Hodgkin's Disease 1–year 66 71 78 83 69 75 81 82
5—year 31 38 52 Hº º 38 46 56 ſº-
Multiple Myeloma 1-year || 36 43 54 59 41 46 59 || 52
5—year 6 12 16 tºs 8 10 16 tºº
Acute Leukemia 1-year 14 23 32 37 13 19 32 34
(All ages) 5—year 1 2 3. nº º 1 2 4 Emº
Acute Leukemia 1—year 26 40 60 76 21 41 62 71
(Under 15 yrs.) 5–year 1 3 4 tºº 1 5 7 ºmn
Chronic Leukemia 1-year || 56 61 69 68 58 61 71 67
5—year 22 25 29 tºm; 24 31 31 * = .
*Source: End Results in Cancer, Report No. 4
f Provisional Rates
CANCER OF BUCCAL CAVITY AND PHARYNX.
| , ， \，\!

LIP: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
tº gº ºn ºn tº sº tº º ſº tº ſº º ºs ºº tºº sº. ***--------------- ---------------EBHARA
1960-64 1965:63 1970-71 1960-64 1965-69 1970-71
NUMBER OF CASES 1063 79.2 186 82 67 . 15
PERCENT_CLASSIFIED_AS:
LOCALIZ ED 9 1 88 83 89 83 87
REGIONAL 7 10 1 0 7 12 13
DISTANT 1 2 5 0 l! O
UNKNOWN 1 1 1 l! 1 0
PERCENT_TREATED_BY:
SURGERY ON LY - 79 8 l; 81 79 75 87
RADIATION ONLY 1 l; 10 13 13 21 O
SUR G+RAD ONLY l! 2 2 l, 1 O
NONE J 2 2 l! 2 3 13
SURVIVAL_RATE (%). (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES
1 - YEAR 97 (93) 97 (9.3) 9 l; (89) 1 00 (96) 97 (93) × 3% (**)
3- YEAR 91 (79) 88 (76) 93 (83) 88% (75%)
5- YEAR 87 (68) 8 l; (65) 80% (67*) 87 k (67*)
LOCA LIZED \ -
1- YEAR 99 (95) 1 00 (95) 9 6 (91) 99 (96) 102* (96+) xxº: (**)
3- YEAR 9 tº (82) 9 1 (78) 95 (86) 93% (79*)
5- YEAR 90 (71) 87 (67) 83% (70*) 91+ (70%)
REGIONAL - -
1- YEAR 80% (75%) 83 (79) 93+ (88%) × 2 × (**) × 3. (**) sk 2% (**)
3- YEAR 52+ (l, 3+) 71 + (53%) #: ; (**) x 2k (**)
5- YEAR 51* (384) 714 (52*) § 2; (**) xt x: (**)
DIST ANT
1 - YEAR ×2k (**) * * (**) >k × (**) × x (**) 2& 3 k (**) xx xk (**)
3- YEAR x:2y: (**) 2%. 3% (**) * x (*#) * 2: (**)
5- YEAR Sk:k (**) >}< xk (**) - × 2% (**) 2% ºr (**)
*RATES HAVE A STANDARD ERROR BETWEEN 5 AND 1 0 PE RCENT. *
**NUMBER OF CAS ES TOO SMALL TO YIELD RELIABLE RAI ES, OR STANDARD ERROR GREATER THAN 1 0 PERCENT .
TONGUE: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
---AAkH----——————— --------------- FEMALE
1960-65 965–69 1970-71 1960-64 1965-69 1970-71
NUMBER OF CASES 10 l; l; 966 377 360 l! 26 174
PERCENT_CLASSIFIED_As:
LOCALIZED 39 34 31 l; 9 l; 6 l!7
REGIONAL 5 1 l! 6 l, l; l, l; l: 1 31;
DISTANT 6 18 23 l! 11 15
UNKNOWN t! 2 2 3. 2 l!
PERCENT TREATED BY:
SURGERY ON LY 25 21 2 l; 33 30 29
RADI ATION ONLY l, 9 l; 9 55 l; 6 U, 5 l, 7
SUR G+RAD ONLY 12 17 11 13 13 16
CHEMO/HORM ONLY () 1 O f O 1
RAD+CHEMO/HORM 7 6 6 3 6 5
SUR G+RAD+C HEMO/HORM 1 2 2 O 2 O
NONE 6 l! 2 l! l! 2
SURVIVAL_RATE__(#): (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES
1 - YEAR I 61 (59) 64 (6.2) 63 (60) 71 (72) 73 (71) 77 (75)
3- YEAR 33 (29) 37 (33) 51 (47) l; 9 (l; 5)
5- YEAR 25 (20) 29 (23) l, 5 (39) l! 2 (36)
LOCALIZED - r
1- YEAR 83 (80) 85 (82) 82 (79) 88 (86) 93 (90) 90 (88)
3- YEAR 56 (50) 61 (51) 71 (65) 69 (63) -
5- YEAR 44 (35) 53 (4.2) 62 (53) 58 (49)
REGIONAL
1- YEAR l;9 (l; 7) 58 (56) 58 (56) 62 (61) 61 (60) 75% (73*)
3- YEAR 19 (16) 30 (26) 3 (; (31) 36 (33) *
5- YEAR 14 (11) 20 (16) . 30 (26) 32 (29)
DIST ANT w *
1 - YEAR 33+ (32+) 43 (4.2) 47+ (45+) ++ (++) l, 9% (48*) ++ (++)
3- YEAR 8+ ( 8+) 15 (13) . # * (**) 27# (25+)
5- YEAR 4 + ( 3+) 12 (10) ++ (++) 22* (19*)
*RATES HAVE A STANDARD ERROR BETWEEN 5 AND 10 PERCENT.
* + NUMBER OF CAS ES TOO SMALL TO YIELD tº ELIABLE RAI ES, OR STANDARD ERROR GREATER THAN 10 PERCENT .
3
SALIVARY GLAND: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVALRATES
NUMBER OF CASES
PERCENT_CLASSIFIED_AS:
LOCALIZED
REGIONAL
DISTANT
UNKNOWN
PERCENT TREATED_BY:
SURGERY ON LY
RADIATION ONLY
SUR G + RAD ONLY
SURG+CHEMO/HORM
RAD+CHEMO/HORM
SURG+RAD+C HEMO/HORM
NONE
SURVIVAL_RATE– (#):
ALL STAGES
1 - YEAR
3- YEAR
5- YEAR
LOCALIZED
1- YEAR
3- YEAR
5- YEAR
REGIONAL
1- YEAR
3- YEAR
5- YEAR
DIST ANT
1 - YEAR
3- YEAR
5- YEAR
1960-64
8 O
66
60
92
87
85
69*
l; 6:
3.32k
×2%
::::
sk: ;
265
5 l;
35
65
11
16
1
1
1
5
(77)
(59)
(1,8)
(89)
(79)
(72)
(66*)
(39*)
(26*)
(**)
(++)
(**)
––––HARE---
1965-6
75
65
62
91
88
85
68 k
50 k
l, 8%
1, 2*
2 iſ +
1 l; *
* RATES HAVE A STANDARD ERROR BETWEEN 5 AND
**NUMBER OF CAS ES TOO SMALL TO YIELD & E LIAB.L.E RATES,
275
51
31
15
57
14
:
(74)
(57)
(5.0)
(88)
(79)
(71)
(65+)
(l, 3+)
(38%)
(40%)
(20+)
(10+)
754.
10 12k
8.3%
×2k
10 PERCENT .
1 O
(OBSERVED RATES SHOWN IN PARENTHESES)
(71*)
(96*)
(78+)
(**)
1960-61;
239
63
27
6
l;
68
1:
3
O
2
6.
88 (86)
80 (75)
80 (71)
96 (94)
93 (88)
92 (84)
82% (80+)
59* (55*)
57+ (50+)
× 3% (**)
* 3: (**)
2K 2. (**)
FEMALE
1965-69 1970-71
237 70
60 56
28 23
10 20
2 1
65 60
7 11
2 l; 27
O 1
O O
1 0
2 O
88 (86) 86 (84)
78 (73)
75 (66)
98 (96) 96 (94)
92 (87)
91 (81)
81% (79%) 89+ (87+.)
66+ (62+)
60+ (53*)
2, 3, (**) × 3% (**)
3::: (**)
:::: (**)
OR STANDARD ERROR GREATER THAN 10
PERCENT .
E.
FLOOR OF MOUTH: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
FLOOR OF MOUTH 2.
1960-64
NUMBER OF CAS ES 631
PERCENT_CLASSIFIED_AS:
LOCALIZED l; l;
REGIONAL l, 9
DISTANT 5
UNKNOWN 2
PERCENT_TREATED_B.Y.:
SURGERY ON LY 36
RADIATION ONLY l; 0
SUR G + RAD ONLY 11
CHEMO/HORM ONLY 1
RAD+CHEMO/HORM l;
SUR G+RAD+C HEMO/HORM 1
NONE 7
SURVIVAL RATB (#):
ALL STAGES -
1- YEAR 73 (70)
3- YEAR l;9 (l, 3)
5- YEAR l, 1 (33)
LOCALIZED
1 - YEAR 91 (87)
3- YEAR 70 (62)
5- YEAR 58 (47)
REGIONAL
1- YEAR 63 (61)
3- YEAR 35 (30)
5- YEAR 28 (22)
DISTANT
1 - YEAR 28+ (27*)
3- YEAR 19+ (17+)
5- YEAR 21+ (17+.)
* RATES HEAWE A STANDARD ERROR BETWEEN
# *NUMBER OF CAS ES TOO SMALL TO YIELD RELIABLE RATES,
––––AAkk–––
1965:63 1970-71
81 1 271,
35 30
52 59
1 O 8
3 3
32 32
39 l; 1
17 18
1 1
5 3
1 1
5 3
75
l, 9
42
87
69
59
72
4.3
37
l; 9 k
20*.
1 l; +
5 AND
(72) 77
(l! (!)
(34)
(84) 90
(64)
(l! 9)
(69) 75
(38)
(30)
(474) *:k
(18+)
(11+)
10 PERCENT.
(OBSERVED RATES SHOWN i N PARENTHESES)
(74)
(87)
(72)
(**)
OR STANDARD ERROR
1960-61;
206
5 l;
L; 1
3
2
50
.3 l;
8
1
3
0
3
82 (80)
62 (58)
55 (49)
89 (87)
77 (73)
68:k (62*)
724 (70*)
45+ (42*)
374 (33*)
:: *k (**)
2: 3: (**)
2K 3% (++)
STAGE AND Ta EAEMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
—FEMALE
1965-69
28 1
37
50
11
2
39
33
19
0
l;
0
l;
75 (74)
55 (51)
l; 7 (41)
90 (88)
81 (76)
78% (70+)
72 (70)
l, l; (I, 1)
30 (27)
48° (47%)
22# (20+)
15+ (134)
GREATER THAN 10 PERCENT .
77
90 ×
78+
x *
(75)
(88+)
(76*)
(**)
s
OTHER MOUTH: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
––––Płękº, FEMALE
1960-61; 1965-69 1970-71 1960-64 1965-69 1970-71
NUMBER OF CAS ES 685 578 228 303 31, 2 111
PERCENT_CLASSIFIED_AS:
LOCALIZ ED l; 5 34 32 50 l; 6 35
REGIONAL l; 6 l; 6 l; 8 l! 3 33 l!3
DIST ANT 6 17 17 l! - 18 17
UNKNOWN 3 3 3 3 3 5
PERCENT_TREATED_B.Y.: -
SURGERY ON LY 32 e 26 26 l;0 37 32
RAD IATION ON LY - l, 7 l; 8 l, l; 37 35 l!!
SUR G+RAD C NLY 10 1 4 16 11 16 1 l;
CHEMO/HORM ONLY O 1 1 O 1 O
R AD+CHEMO/HORM 3 5 l! l; l! 3
SUR G+RAD+C HE MO/HORM 1 2 1 1 2 3
NONE 7 l! 7 7 5 l!
SURVIVAL_RATE__(#): (CBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES
1 - YEAR - 73 (69) 75 (72) 69 (66) 72 (69) 76 (74) 81 (78)
3- YEAR l; 8 (l; 1) 48 (4.2) 51 (l; 6) 56 - (51)
5- YEAR 38 (29) l! 0 (32) l; 6 (39) l, 7 (40)
LOCALIZED
1- YEAR 86 (8.1) 90 (86) 88 (8.5) 88 (85) 91 (88) 9 3 (92)
3- YEAR 65 (55) 67 (59) 72 (66) 76 (70)
5- YEAR 55 (42) 6.3 (5.0) 67 (58) 68 (59)
REGIONAL y
1- YEAR 6 l; (61) 71 (6 8) 70 (67) 60 (58) 70 (68) 7 14: (72*)
3- YEAR 37 (31) + 2 (37) i 33 (29) l. 34: (l; 0+)
5- YEAR 26 (20) 32 (26) 26 (22) 3.2% (27*)
DIST ANT t
1 - YEAR U 3× (l, 1+) 57% (54*) 3.9% (37+.) × -k (**) 5 lººk (52+) × 5]: (++)
3- YEAR 23# (20+) 27 & (24%) # 3& (**) 3 04: (27*)
5- YEAR 19x (14*) 1 9 × (15+) × 3% (**) 22+ (18+)
*RATES HAVE A STANDARD EFFOR BETWEEN 5 AND 10 PERCENT.
* * NUMBER OF CAS ES TOO SMALL TO YIELD H E L i AB L E. & AI ES, OR STANDARD ERROR GREATER THAN 10 PERCENT .
&
TOTAL PHARYNX: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
––––HAkk--- FEMALE
1960-64 1265–69 1970-71 1960-64 1965-69 1970-71
NU MiB ER OF CAS ES 153 l; 16 96 615 l; 33 555 239
EEEcent classified as:
LOCALIZED 25 18 19 31 22 23
REGIONAL 59 53 5 1 57 . 52 l, 9
DIST ANT 11 24 26 9 22 23
UNKNOWN 5 5 t! - 3 l; 5
PERCENT_TREATED_B.Y.:
SURGERY ONLY 10 8 7 7 7 6
RA DIATION ONLY 62 5 9 60 63 63 6l;
SU R G + RAD O NLY 12 18 20 15 16 18
CHEMO/HORM ONLY O 1 1 1 1 O
RAD+CHE MO/HORM 7 6 5 6 7 7
SUR G + RAD+C HE MO/HO RM 2 2 2 O 1 1
NONE 7 5 5 7 5 l!
SURVIVAL_HATE__(X) : (OBSERVED RATES SHOWN IN PARENTHESES)
AL L STAGES
1 - YEAR 57 (55) 60 (58) 60 (58) 6 l; (62) 66 (64) 63 (62)
3- YEAR 28 (25) 31 (28) 37 (35) 36 (31)
5- YEAR 21 (17) 21 (1 3) 34 (30) 28 (25)
Local IZED
1 - YEAR 75 (72) 7 Z (70) 73 (70) 75 (74) 78 (77) 87 (86)
3- YEAR ! 3 (39) l! 3 (38) 51 (l, 8) 52 (48)
5- YEAR tº 35 (2.9) 31 (26) l, 7 (l; 2) l, 3+ (39*)
REGIONAL
1 - YEAR 55 (53) 63 (61) 66 (611) 63 (61) 66 (65) 67 (66)
3- YEAR 25 (23) 34 (31) 35 (33) 36 (33)
5- YEAR 19 (15) 44 (20) 32 (29) 27 (24)
DIST ANT
1 - YEAR 36 (3 4) 45 (44) l! 2 (1, 1) 30+ (29*) 51 (50) 38+ (37+.)
3- YEAR 15 (1 t!) 18 (16) 8+ ( 8+) 21, (22)
5- YEAR 8 ( 7) 10 ( 8) 6+ ( 5*) 14 (13)
* RATES HAVE A STANDARD ERROR BETW EEN 5 Å in D 1 0 PERCENT .
NOTE: TOTAL PHARY NX INCLUDES UNSPEL i FIL 1) PAF. ES OF PHARY NX.
$
MESOPHARYNX: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
----------------MA**--------------- *. FEMALE
1960-64 1965-69 1970-71 1960–65 1965-69 1970-71
NUMBER OF CASES 652 77 9 292 215 292 { 139
PERCENT_CLASSIFIED_AS:
LOCALIZED 29 19 20 31 25 24
REGIONAL 55 55 55 60 53 53
DISTANT 11 22 21 5 18 22
UNKNOWN 5 l; l! l! l! 1
PERCENT-TREATED_B.Y.
SURGERY ON LY 8 8 8 6 7 5
RADIATION ONLY 62 61 58 61 62 63
SURG+ RAD ONLY 13 17 21 21 18 22
CHEMO/HORM ONLY 1 O O 1 1 O
RAD+CHEMO/HORM 7 7 l! l! 6 8
SURG+RAD+C HEMO/HORM 2 2 2 O 2 1
NONE 6 5 7 6 l! 1
SURVIVAL_RATE__(#) : (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES -
1 - YEAR 62 (60) 66 (64) 6 l; (6.2) 70 (68) 71 (70) 68 (67)
3- YEAR 33 (29) 38 (34) l; 6 (t; 3) l, 6 (l! 3)
5- YEAR 26 (21) 27 (22) l; 1 (36) 36 (33)
LOCALIZED - *,
1- YEAR 82 (79) 79 (77) 78% (76%) 83 (82) 81 (79) 944 (93*)
3- YEAR 56 (50) 53 (48) 594 (56+) 56+ (53*)
5- YEAR - tº 5 (37) # 1 (35) 51* (47%) 50% (454)
REGIONAL -
1- YEAR 58 (56) 68 (66) 71 (68) 67 (65) 71 (69) 66+ (64*).
3- YEAR 25 (22) t; 0 (36) l! 5 (1, 1) l; 6 (l, 3)
5- YEAR 19 (16) 28 (2 3) l; 1 (35) 36 (33)
DIST ANT
1- YEAR 32% (31*) 50 (l) 8) l, 1+ (1,0+) 3& 2x (**) 57+ (56*) l, 6+ (45+)
3- YEAR 14+ (12+) 22 (19) sk ºr (**) 34+ (32*)
5- YEAR 7+ ( 6+) 12 (10) - 2: 3: (**) 17+ (16+)
*RATES HAVE A STANDARD ERROR BET WEEN 5 AND 1 0 PERCENT. i
** NUMBER OF CASES TOO SMALL TO YIELD tº ELIAE L E HATES, OR STANDARD ERROR GREATER THAN 10 PER CENT .
G.
NASOPHARYNX:
NUM BER OF CASES
PERCENT_CLASSIFIED_AS:
arºº ºmsºmeºsºme º Aºmºsºmsºmatºesºmºsºmºsºme
LOCALIZED
REGIONAL
DIST ANT
UNKNOWN
PERCENT_TREATED_B.Y.:
SURGERY ONLY .
RADIATION ONLY
SUR G+RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
RAD+CHEMC/HORM
SURG+RAD+C HEMO/HORM
NONE
SURVIVAL_RATE (Ali.
ALL STAGES
1- YEAR
3- YEAR
5- YEAR
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIO-NAL
1- YEAR
3- YEAR
5- YEAR
DISTANT .
1- YEAR
3- YEAR
5- YEAR
STAGE AND TREATMENT; DISTRIBUTIONS: RELATIVE SURVIVAL RATES
–––HARE---
1960-6 l; 1965:63
250 265
20 1 9
58 45
18 31
l; 5
3 2
70 72
10 13
2 1
1 1
6 5
2 2
6 3
76+
l. 34:
39×
6 l;
l;0
27
t! 04:
16+
10+
(60)
(33)
(23)
(74+)
(1,04)
(34+)
(63)
(38)
(24)
(39*)
(15*)
( 94)
(OBSERVED R AT&S SHOWN
68
36
25
7.8%
# 5*
36+
5 l; +
23#
16 &
;
1
IN PAREN THESES)
(66)
(34)
(2.2)
(76%)
(i, 1 + )
(31+)
(71)
(l; 0)
(25)
(53*)
(21*)
(14%)
60%:
*:::
62+
l, 9.4:
*RATES HAVE A STANDARD ERROR BETWEEN - 5 AND 1 0 PERCENT . -
**NUMBER of CASEs Too SMALL To YIELD RELIABLE RATES, OR STANDARD ERROR GREATER THAN 10 PERCENT.
(58+)
(**)
(6.1+)
(48*)
FEMALE
1960-64 1965-69
95 109
32 13
l, 9 5 l;
16 28
3 5
5 2
69 73
13 1 l;
2 1
O O
5 8
O 1
5 1
6 (; 4 (63*) 68 (67)
37+ (35+) 3 l (32)
35+ (32*) 2 l; (22)
69* (67+.) 2% xk (**)
51* (47+.) 2::: (**)
*:: (**) 2% ºt (**)
71+ (70*) 714 (69%)
35% (34+) 30+ (284)
34+ (32+) 19+ (17+)
3, 2% (**) 534: (53*)
2k xk (**) 21+ (20+)
x: x < (**) 0-k ( O+)
1970-71
l!8
21
39
27
13
O
73
10
2
O
8
O
6
57+ (56+)
x: x (**)
x 2k (**)
:::: (**)
3,
HYPOPHARYNX: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
er
tº sº tº ºs use ºs º ºsmºs ºn sº wºme sºme tº sº mº sº, HALs--- tº ºme º smº * FEMALE. * * * * *
1960-64 1992-92 1970-71 1960-64 1965-69 1970-71
NUMBER OF CASES t| 6.9 560 223 86 127 l;2
PERCENT_CLASSIFIED_AS: º
LOCAL IZED * 22 1 7 19 31 21 26
REGIONAL 6 l; 5.3 l, 9 58 50 t;5
DIST ANT 9 25 27 9 27 26
UNKNOWN 5 5 5 2 2 3
PERCENT TREATED_B.Y.: w
SURGERY ONLY 17 14 9 13 11 19
RADIATION ONLY 57 50 56 63 58 57
SUR G+ RAD ONLY 12 24 25 8 13 17
R AD+CHEMO/HORM 5 5 l! 7 8 2
SURG+RAD+C HEMO/HORM 1 3 3 O O O
NONE 6 6 3 9 9 5
SURVIVAL_RATE__(#): (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES •
1 - YEAR 5l. (52) 51 (5.0) 57 (55) 52% (51*) 53 (52) 51* (51*) .
3- YEAR 23 (20) 22 (20) 23+ (22*) 18 (17)
5- YEAR 16 (13) 1 3 (11) 23+ (20+) 11 (10)
LOCAL I ZED t
1- YEAR 65 (63) 6 4+ (6.1#) 64+ (60+) 65+ (63+) 724 (70+) × 3% (**)
3- YEAR 26+ (23*) 27+ (2 4*) 3.14 (28+) 2% ºr (**)
5- YEAR 17+ (14+) 15+ (11+ ) sk sº (**) × xk (**)
REGIONAL
1 - YEAR 53 (51) 55 (5.3) 64+ (62%) l, 9% (1, 8+) 53+ (52*) :::: (**)
3- YEAR 23 (20) 24 (2.2) 234 (22+) 18+ (17+)
5+ YEAR 17 (14) 1 7 (14) 22% (20+) 13+ (11+)
DIST ANT
1 - YEAR l! 04 (39*) 37 (36) l, 1+ (40+) k .2% (**) 394 (38+) × 3% (**)
3- YEAR 18+ (16+) 13 (12) $2% (**) 9+ ( 94)
5- YEAR 12+ ( 94) 3 ( 3) × 3 × (**) 3+ ( 3+)
*RATES HAVE A STANDARD ERROR BETWEEN 5 AND 1 0 PERCENT.
* * NUMBER OF CAS ES TOO SMALL TO YIELD RELIABLE KATES, OR STANDARD ERROR GREATER THAN 10 PERCENT .
CANCER OF DIGESTIVE SYSTEM
ſ „ſ. №ſſ)

&
ESOPHAGUS. STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
NUMBER OF CASES
LOCALIZED
REGIONAL
DISTANT
UNKNOWN
PERCENT TREATED_B.Y.:
SURGERY ON LY
RADIATION ONLY
SUR G+RAD ONLY
CHEMO/HORM ONLY
RAD+CHEMO/HORM
NONE
SURVIVAL BATE– (#):
ALL STAGES
1 - YEAR
3- YEAR
5- YEAR
LOCALIZED
1- YEAR
3- YEAR
5 - YEAR
REGIONAL
1 - YEAR
3- YEAR
5- YEAR
DIST ANT
1- YEAR
3- YEAR
5- YEAR
——AAkk——
1965–69
1341
(OBSERVED RATES SHOWN IN PARENTHESES)
19
6
3
30
1 0
6
1
:
:
(19)
( 5)
( 2)
(28)
( 9)
( !)
(18)
( !)
( 2)
( 6)
( 2)
( 1)
21
(20)
( 3)
( 2)
(31)
( 6)
( 3)
(19)
( 3)
( 3)
(10)
( 2)
( 1)
26
39
3 l; +
11
*RATES HAVE A STANDARD ERROR BETWEEN .5 AND 1 0 PERCENT .
+ + NUMBER OF CASES TOO SMALL TO YIELD H E LIABLE BATES,
(25)
(37)
(32*)
(11)
1960-64
l! 02
l; 1
32
18
9
18
l, 9
7
O
3
23
28 (27)
8 ( 7)
6 ( 5)
l; 1 (39)
17 (15)
1 L, (11)
2 l; (21)
3 ( 3)
1 ( 1)
l! ( !)
O ( 0)
O ( 0)
OR STANDARD ERROR
FEMALE-
1965-69
l; 6 l;
37
25
22
16
13
55
8
1
l;
18
27 (26)
9 ( 8)
6 ( 5)
37 (36)
11 ( 9)
8 ( 7)
23 (23)
12 (11)
8 ( 7)
13 (12)
1 ( 1)
× 2): (**)
GREATER TH AN 10 PERCENT .
1970-71
26
37+
25-k
17+
176
26
23
30
21
13
65
1 l;
(25)
(35+)
(24+)
(17+)
&
STOMACH: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
–––MALE ---reai-------'* * * * * *
1960-64 1965-69 1970-71 1960-64 1965-69 1970-71
NUM BER OF CASES 3 008 2376 89.3 1755 1 380 511
PERCENT_CLASSIFIED_AS:
LOCAL IZED 16 16 15 21 22 20
REGIONAL 3 l; 30 29 33 28 26
DIST ANT l;5 l! 7 1, 8 l! 0 l! 3 l;5
UNKNOWN 5 7 8 6 7 9
PERCENT_TREATED_B.Y.:
SURGERY ON LY l; 1 l! 2 39 l; 1 l! 2 t!0
RADIATION ONLY l! 4 5 3 3 3
SUR G+RAD ONLY 1 2 2 2 2 2
CHEMO/HORM ONLY 6 10 12 6 9 1 l;
SURG+CHEMO/HORM 2 2 3 2 3 l!
RAD+CHEMO/HORM 1 1 5 2 1 l!
NONE l, l; 37 3 l; l; l; 39 32
SURVIVAL RATE (#): (OBSERVED RATES SHOWN IN PARENTHESES)
AL L STAGES -
1 - YEAR 30 (28) 31 (29) 32 (30) 3.3 (31) 35 (31) 33 (31)
3- YEAR 1 l; (12) 15 (13) 17 (15) 18 (16)
5-YEAR 10 ( 8) 12 ( 9) 1 l; (11) 1 l; (11)
LOCALIZED
1- YEAR 63 (59) 67 (62) 67 (63) 59 (56) 70 (67) 64+ (6.1#)
3- YEAR l;5 (37) l, l; (36) ºl. 1 (36) 51 (l, l;)
5- YEAR 38 (27) i! 0 (29) 37 (29) l! 3 (33)
REGIONAL -
1 - YEAR L; 1 (39) 47 (l; 5) l; 7 (l; 5) l! l; (1,2) 50 (l; 8) l; l; (l, 3)
3- YEAR 15 (13) 21 (18) 20 (18) 20 (18)
5 - YEAR 10 ( 8) 14 (11) 15 (12) 13 (11)
DIST ANT. - -
1 - YEAR 10 (10) 10 (10) 15 (14) 13 (13) 10 (10) 16 (15)
3- YEAR 2 ( 2) 2 ( 2) 3 ( 3) 3 ( 3)
5- YEAR 2 ( 1) 1 ( 1) 3 ( 2) 2 ( 1)
*RATES HAVE A STANDARD ERROR BETWEEN 5 AND 1 0 PERCENT,
S
ToTAL colon. STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
-----Häkk--- FEMALE
1960-61; 1965:63 1970-71 1960-61; 1965-69 1970-71
NUMBER OF CA. SES l; l;55 4 485 1705 5342 . 5 196 1912
PERCENT_CLASSIFIED_AS2.
LOCA LIZED - t; 0 # 2 t; 2 L; 0 t! 0 l; 0
REGIONAL 31 27 2 l; 33 28 27
DISTIANT 2 l; 27 30 23 28 28
UN KNOWN 5 l! l! l; l; 5
PERCENT_TREATED_B.Y.:
SURGERY ONLY 76 78 75 76 77 76
RA DIATICN ONLY O 1 1 1 1 1
SURG + RAD ONLY 1 1 1 1 1 1
CHEMO/HORM ONLY 2 3 l! 1 2 3
SURG+CHEMO/HORM 3 4. 6 l; 5 7
SURG +RAD+C HEMO/HORM O 0 O 0 1 1
NONE 17 13 13. 17 1 3 10
SURVIVAL_FiATE_(%) : (OBSERVED RATES S HOW N IN PAR ENTHES ES)
AL L STAGES -
1 - YEAR 63 (60) 67 (6.4) 61 (58) 66 (63) 69 (66) 68 (65)
3- YEAR l!8 (40) 52 (43) 50 (44) 52 (1,5)
5- YEAR l, 1 (31) 43 (32) l, 5 (36) l, 6 (37)
LOCAL IZED
1 - YEAR 83 (79) d7 (82) 81 (77) 86 (83) 89 (85) 87 (83)
3- YEAR 75 (63) 78 (65) 77 (68) 80 (70)
5 - YEAR 68 (50) 71 (52) 72 (59) 74 (59)
REGION AI.
1- YEAR 70 (66) 80 (76) 77 (73) 72 (69) 82 (79) 81 (81)
3- YEAR l;8 (l; 1) 56 (47) 50 (l, l;) 58 (51)
5- YEAR 39 (29) 42 (31) l! (! (36) 50 (1,1)
DISTIANT t
1- YEAR 26 (25) 29 (27) 26 (25) 27 (26) 32 (30) 34 (32)
3- YEAR 8 ( 7) 12 (10) - 8 ( 7) 10 ( 9)
5 - YEAR 5 ( !) 7 ( 6) l! ( !) 7 ( 5)
NOTE: T OT AL COLON INCLUDES OTHER AND UNSPECIFIED PARTS OF COLG N.
N.
ASCENDING COLON, CAECUM, AND APPENDIX:
STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
sºme tº º smºº ºne sº ºne sº ºme ºne º ºs º ºne sº ºne
NUMBER OF CASES
PERCENT_CLASSIFIED_AS.:
LOCALIZED
REGIONAL
DISTANT
UNKNOWN
PERCENT_TREATED_BY:
SURGERY ONLY
RADI ATION ONLY
SUR G+RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
SURG+RAD+C HEMO/HORM
NoNE
SURVIVAL RATB (#):
AL L STAGES
1 - YEAR
3- YEAR
5- YEAR
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIONAL
1- YEAR
3- YEAR
5-YEAR
DIST ANT
1 - YEAR
3- YEAR
5- YEAR
61
l, 7
(; 2
8 l;
77
72
68
l, 7
l; 0
214
9
7
i
1
(58)
(39)
(31)
(80)
(611)
(53)
(6 ly)
(1,0)
(30)
(23)
( 8)
( 5)
67
50
42
88
79
73
77
5 l;
1, 1
33
13
11
(63)
(l; 1)
(31)
(82)
(65)
(52)
(73)
(45)
(30)
(32)
(11)
( 8)
i
1
(OBSERVED RATES SHOWN IN PARENTHESES)
57 (54)
80 (76)
76 (72)
20 (18)
1960-64
1772
39
36
21
l;
79
1
1
1
2
O
15
65 (62)
50 (l, 3)
l, 7 (37)
8 l; (81)
77 (67)
7 l; (58)
70 (67)
l; 9 (l; 3)
l, 7 (36)
25 (24)
l; ( l!)
2 ( 2)
FEMALE
1965-69
1715
39
30
28
3
7 9
O
1
2
5
O
12
67 (64)
53 (46)
l, 8 (37)
88 (83)
82 (70)
77 (58)
81 (77)
60 (52)
53 (41)
27 (26)
10 ( 8)
( !)
1970-71
656
38
32
27
3
78
0
1
l!
6
1
11
65 (62)
8 1 (77)
83 (79)
29 (27)
R}
TRANSWERSE COLON: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
–––HALE---
1960-64 1965-69 1970-71
NUMBER OF CA SES 705 782 288
PERCENT_CLASSIFIED_AS.; -
LOCALIZED 39 1, 2 U. 1
REGIONAL 31 27 28
DIST ANT 27 29 28
UNKNOWN 3 - 2 3
PERCENT_TREATED_B.Y.:
SURGERY ONLY 71, 79 76
SUR G+RAD ONLY 1 1 O
CHEMO/HORM ONLY 2 l! 3
SURG+CHEMO/HORM 3 5 7
NONE 19 1 1 1 l;
SURVIVAL KATE_l(X) : (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES
1 - YEAR 57 (54) 66 (62) 6 l; (60)
3- YEAR l;5 (38) 50 (42)
5- YEAR 37 (28) || || (33)
LOCALIZED -
1- YEAR 80 (76) 88 (83) 84 (79)
3- YEAR 72 (60) 77 (6 l!)
5 - YEAR 61 (l; 5) 70 (51)
REGIONAL w
1 - YEAR - 61 (58) 79 (75) 7 || 3: (70*)
3- YEAR l;2 (36) 55 (l; 7)
5- YEAR 35 (27) t| 6 (35)
DIST ANT
1- YEAR 21 (20) 24 (23) 3 1: (29*)
3- YEAR 9 ( 8) 10 ( 8)
5- YEAR 6 ( 5) 8 ( 6)
* R AT ES HAVE A STANDARD ERROR BETWEEN 5 AND 1 0 PERCENT .
FEMALE
1960-61; 1965-69 1970-71
887 946 3.65
l! 0 l; 0 38
32 29 28
2 l; 28 29
l! 3 5
76 8 0 82
1 1 0
1 2 1
l; 3 7
17 1 3 9
63 (60) 68 (65) 67 (65)
l, 8 (l, 3) 52 (1,5)
|| 3 (34) l; 6 (36)
87 (84) 87 (83) 92 (87)
77 (68) 79 (69)
70 (56) 71 (56)
63 (61) 78 (75) 81 (78)
l, 5 (l, 0) 57 (50)
l; 0 (33) 52 (l; 1)
25 (24) 33 (32) 32 (31)
11 ( 9) 12 (11)
6 ( 5) 8 ( 6)
DESCENDING COLON: STAGE AND TREATMENT DISTRIBUTIONS; RELATIVE SURVIVAL RATES
NUMBER OF CAS ES
PERCENT_CLASSIFIED_AS:
LOCALIZED
REGIONAL
DIST ANT
UNKNOWN
PERCENT_TREATED_BX:
SURGERY ON LY
RAD IATION ON LY
SUR G+RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
RAD+C HEMO/HORM
NONE
1960-64
357
----------------Hélè---------------
1965–62 1970-71
37.8 1 l; l;
|| 6 l; 6
27 26
24 25
3 3
81 8 3
0 1
0 O
2 1
l; 3
0 1
1 3 11
SURVIVAL RATE– (#): (OBSERVED RATES SHOWN IN PARENT HESES)
ALL STAGES
1 - YEAR
3- YEAR
5- YEAR
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIONAL
1- YEAR
3 - YEAR
5- YEAR
DISTANT
1 - YEAR
3- YEAR
5- YEAR
82
75
67+
73
1, 7+
32-k
29*
7+
7+
(63)
(l, 3)
(31)
(78)
(611)
(50+)
(70)
(1,0+)
(25+)
(28%)
( 6*)
( 5+)
* RATES HAVE A STANDARD ERROR BETWEEN
71
57
l; l;
86
73
6 (; ;
86
68%
l; 7:
31 *
21 k
10 *
5 AND
(67) 67
(48)
(32)
(81) 8 lººk
(61)
(l, 6% )
(8.1) 9 0x
(57+)
(35*)
(30°) 21+
(17+)
( 8+)
10 PERCENT .
(64)
(79%)
(86+)
(20+)
1960-64
l! 3 l;
l! 0
35
20
5
78
1
1
1
l!
O
1 l;
66 (61%)
50 (1,5)
l! 3 (36)
85 (82)
7 l; (66)
65 (54)
77 (7 u)
54 (48)
l, 5 (38)
24 (24)
8 ( 7)
t; ( 3)
FEMALE
1965-69
l, 36
l! 3
27
27
3
8 0
O
2
2
6
O
1 0
72 (70)
54 (49)
51 (1,2)
90 (87)
81 (73)
79 (66)
85 (83)
60+ (55*)
54+ (16+)
35 (34)
11 (10)
9 ( 7)
emº ºr sº ºme nº eme * * * * * * * *
1970-71
1 l;2
l;7
30
20
3
85
1
O
3
l!
O
7
76 (74)
86 (83)
92% (89*)
36+ (35+)
3
S.
SIGMOD COLON: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
NUMBER OF CASES
PERCENT_CLASSIFIED_AS:
LCCALIZED
REGIONAL
DIST ANT
UNKNOWN
PERCENT_TREATED_B.Y.:
SURGERY ON I., Y
RA DIATION ONLY
SUR G+RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
SUR G+RAD+C HEMO/HORM
NONE
º, º - - tº- tº ºn tº º ºn tº ºmºm º º ºsme
i
1
SURVIVAL_RATE__(#) : (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES
1 - YEAR
3- YEAR
5- YEAR
LOCALIZED
1- YEAR
3- YEAR
5 - YEAR
REGIONAL
1- YEAR
3- YEAR
5- YEAR
DIST ANT
1- YEAR
3- YEAR
5 - YEAR
67
50
l; l;
8 l;
73
68
7 l;
52
L; 0
30
7
3
(63)
(l; 2)
(32)
(79)
(6.2)
(51)
(70)
(l, l;)
(30)
(28)
( 6)
( 3)
70
54
l! 5
87
81
73
82
57
42
30
11
5
(66)
(4 6)
(33)
(83)
(68)
(54)
(77)
(l; 7)
(31)
(28)
( 9)
( 4)
6 l;
82
78
33
(60)
(78)
(73)
(31)
7 1
l; 8
8.8
78
7 l;
(69)
(l; 8)
(t;0)
(85)
(71)
(62)
(75)
(l, 7)
(37)
(33)
(10)
( 5)
FEMALE
1965-69
1866
l! 3
25
27
5
76
1
1
1
7
1
1 3
73 (70)
52 (1,6)
l, 5 (37)
91 (88)
79 (70)
72 (59)
85 (82)
56 (50)
l; 7 (39)
36 (35)
11 (10)
7 ( 6)
73
90
88
l; 0
(70)
(87)
(85)
(38)
§
NUM BER OF CASE S
ºs tº
EFCENT_CLASSIFIED_AS3
LOCALIZED
REGIONAL
DIST ANT
UN KNOWN
PERCENT_TREATED_B.Y.:
SURVIVAL. RATE_ ($) :
SURGERY ON LY
RA DIATION ONLY
SUR G + RAD C NLY
CHEMO/HCRM ONLY
SURG+CHEMiO/HORM
R AD+CHEMC/HORM
SURG+ RAD+C HEMO/HORM
NONE
ALL STAGES
1 - YEAR
3- YEAR
5- YEAH.
LOCALIZED
1 - YEAR
3- YEAR
9 - YEAR
REGIONAL
1 - YEAR
3- YEAR
5 - YEAR
DIST ANT
N D TE :
1 - YEAR
3- YEAR
5- YEAR
HAAR---
1960-64 1265-69
25.36 2.793
l, l; || 6
32 26
20 23
l, 5
70 71
3 l;
2 3
2 4
2 3
O 1
0 1
21 15
65
iſ lº
36
81
67
59
70
l; 0
27
26
l;
3
(62)
(37)
(27)
(77)
(56)
(l, l;)
(66)
(34)
(21)
(25)
( !)
( 2)
69
48
l;0
87
75
67
7 l;
46
31
31
6
2
(65)
(141)
(30)
(83)
(64)
(50)
(71)
(39)
(24)
(29)
( 6)
( 2)
TOTAL E SCIUM INCLUDES RECTUM, & ECIOSIGMOID,
1
(OBSERVED FATES SHOWN in P AREN THESES)
67 (63)
81 (77)
79 (76)
39 (37)
TOTAL RECTUM: STAGE AND TREATMENT DISTRIBUTIONS, RELATIVE SURVIVAL RATES
FEMALE
1960-64 1965-69 1970-71
1973 2 175 809
l; 5 l; 6 l!6
32 27 24 ,
18 22 2||
5 5 6
70 67 69
3 l; l!
1 3 2
2 2 2
l! 8 7
O 0 1
0 O 1
20 16 1 l;
70 (67) 72 (69) 70 (68)
l, 9 (l, 3) 51 (1,5)
39 (32) l;2 (34)
88 (8.5) 88 (85) 88 (85)
75 (67) 75 (66)
6 l; (52) 67 (54)
7 1 (68) 8 l; (81) 83 (80)
l, 1 (37) 5 l; (l; 9)
29 (24) 39 (33)
30 (29) 29 (28) 32 (31)
5 ( 5) 6 ( 6)
1 ( 1) l! ( 3)
A ND UNS tº ECIFIED PARTS OF RECT UMe
&
RECTUM: STAGE AND TREATMENT DISTRIBUTIONS, RELATIVE SURVIVAL RATES
NU MBE & OF CAS ES
PERCENT_CLASSIFIED-AS:
LOC A LIZ ED
REGION AL
D IST ANT
UNKNOWN
NT_TREATED_B.Y.:
RGERY ON LY
R AD iſ ATION ONLY
SUR G +R AD ONLY
CHEMO/HOE.M ONLY
SURG+CHEMC/HORM
R A D +CHEMC/HORM
SURG+ RAD+C HEMO/HORM
NONE
SURVIVAL EATE_(#):
ALL ST A GES
1- YEAR
3- YEAR
5- YEAR
LOCAL IZED
1 - YEAR
3- YEAR
5- YEAR
RE GT ON AL
1 - YEAR
3- YEAF
5 - YEAR
Dr STANT
1 - YEAR
3- YEAR
5- YEAR
65
l; 5
36
81
67
59
70
t! 0
27
2||
3
2
2
(62)
(38)
(27)
(76)
(56)
(l, 3)
(67)
(35)
(21)
(23)
( 3)
( 1)
MAla#–.
1963–69 1970-71
204 0 725
# 8 l; l;
26 25
21 25
5 6
7 O 67
l; 5
l; 3
2 5
2 l;
1 2
1 1
16 13
68
48
39
87
74
65
7 3
43
27
28
6
1
(b5)
(41)
(2.9)
(82)
(6.2)
(H 3)
(6 9)
(38)
(21)
(26)
( 5)
( 1)
68
80
82
l! 0
(OBSERVED RATB.S SHOWN IN PARENTHESES)
(6 ly)
(76)
(78)
(38)
FEMALE º º º
1960-64 1965-69 1970-71
1376 1513 526
l! 6 l; 7 L}8
32 26 22
17 21 22
5 6 8
69 66 69
3 l; 5
2 3 3
2 2 3
3 7 5
O O 1
O O 1
21 16 13
7 1 (68) 72 (69) 72 (69)
l; 8 (43) 50 (l! (!)
38 (31) l; 1 (31)
87 (84) 88 (85) 87 (83)
73 (65) 7 l; (65)
63 (51) 67 (54)
72 (69) 83 (8.1) 81 (78)
39 (35) 50 (l; 6)
27 (23) 3 l; (29)
31 (30) 28 (27) l; 0 (38)
5 ( 5) 5 ( 5)
1 ( 1) 3 ( 3)
S
RECTOSIGMOID: STAGE AND TREATMENT DISTRIBUTIONS, RELATIVE survival RATES
NUMBER OF CASES
PERCENT_CLASSIFIED_AS:
LOCALIZED
REGIONAL
DIST ANT
UNKNOWN
PERCENT_TREATED_B.Y.:
SURGERY ON LY
RADIATION ONILY
SURG+RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
RAD+C HEMO/HORM
NONE
sº ºn
1
SURVIVAL_RATE_(?) ... (OBSERVED RATES SHOW N IN PARENTHESES)
ALL STAGES
1 - YEAR
3- YEAR
5- YEAR
LOCALIZED
1- YEAR
3- YEAR
5 - YEAR
REGIONAL
1 - YEAR
3- YEAR
5- YEAR
DIST ANT
1- YEAR
3- YEAR
5- YEAR
70
l, 5
37
85
69
63
78
l, l;
30
33
8
6
(67)
(39)
(28)
(81)
(58)
(l) 8)
(75)
(38)
(23)
(31)
( 7)
( 4)
70
iſ 9
l! 1
8 S
80
73
77
52
41
36
8
t!
(66)
(42)
(31)
(8 it)
(67)
(5 l;)
(74)
(45)
(32)
(34)
( 7)
( 3)
65
8 l;
73 +
37+
* RATES HAVE A STANDARD ERROR BETWEEN 5 AND 1 0 PERCENT,
(6.2)
(79)
(70*)
(35%)
* * * * * * * * * * * * * * * tº º
1960-64
558
l! l;
3 l;
19
3
75
1.
1
1
6
O
16
71 (69)
54 (1,8)
l! 3 (35)
91 (88)
8 0 (72)
69 (57)
72 (70)
l, 9 (l, l; )
3 l; (28)
28 (27)
5 ( 5)
1 ( 1)
tºº sº - tº tº º- - º ºs º- º ºs º- -
FEMALE
1965-69
662
l; 2
28
26
l!
69
2
1
2
9
1
15
71 (68)
53 (l, 8)
l, l; (36)
87 (84)
78 (69)
66 (5 l;)
85 (83)
62 (57)
51 (l, 3)
32 (31)
9 ( 8)
5 ( !)
67
91
87
20
(61%)
(88)
(85)
(19)
&
LIVER STAGE AND TREATMENT DISTRIBUTIONS, RELATIVE SURVIVAL RATES
NUMBER OF CAS ES
LOCALIZED
REGIONAL
DISTANT
UNKNOWN
PERCENT_TREATED_B.Y.:
SURGERY ONLY
RADIATION ONLY
SUR G+RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
RAD+CHEMO/HORM
NONE
SURVIVAL KATE (%).3.
ALL STAGES
1 - YEAR
3- YEAR
5-YEAR
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIONAL
1- YEAR
3- YEAR
5- YEAR
DIST ANT
1- YEAR
3- YEAR
5- YEAR
* * * * * * * ºne º sº gº tº tº º ºsmº uºmº.
PERCENT_CLASSIFIED_AS:
1-
i
7
2
i
(OBSERVED RATES SHOWN IN PARENTHESES)
::.
:
( 6)
( 3)
( 2)
(11)
( 5)
( l;)
8)
3)
0)
:
2)
0)
0)
:
10
6
l;
21
17
12
:
( 9)
5)
3)
(20) 113.
(15)
( 9)
( 9) 1 1 +
( 5)
( 5)
5)
2)
1)
*RATES HAVE A ST ANDARD ERROR BETWEEN 5 AND 1 0 PERCENT .
( 7)
(11+)
(10+)
( !)
*E* sº sº tº ºn tº º ºs º wº, º ºſmº º ºsmº tº
1960-64
177
33
21
3 l;
12
7
7
O
18
O
3
65
16 (16)
6 ( 6)
7 ( 6)
23* (22*)
13+ (12*)
1 u% (12*)
16+ (16+)
3× ( 3*)
3-k ( 3*)
10 (10)
2 ( 2)
2 ( 2)
1965-69
172
31
9
l! 3
17
15
3
O
18
1
2
61
23 (23)
1 O ( 9)
8 ( 7)
50-k (l, 94)
29* (27+.)
25+ (22+)
14% (13+)
0+ ( 0+)
0+ ( 0+)
9 ( 9)
2 ( 1)
O ( 0)
$ºme tºmsgººms
2 lººk
× 2.
2: 3;
12+
63
25
1 l;
12
(23*)
(**)
(**)
(12+)
§
* GALLBLADDER AND DUCTS:
STAGE AND TREATMENT DISTRIBUTIONS; RELATIVESURVIVALRATES
* - -º, sº gº ºn - *-s sº mºm º - * * * * *A**---------------
1960-64 1965-69 1970-71
NUM BER OF CASES l! 34 387 121
PERCENT_CLASSIFIED_AS:
LOCAL IZ ED 26 29 24
REGIONAL 38 35 l!2
DIST ANT 32 33 - 29
UNKNOWN l; 3 5
PERCENT_TREATED_B.Y.:
SURGERY ON I. Y. 30 37 l! 3
RADI ATION ONI, Y 1 2 3
SUR G + RAD ONLY 2 1 1
CHE MO/HORM ONLY 5 5 12
SURG+CHEMO/HORM 1 2 3
R AD+CHE MO/HORM 1 1 1
NONE 59 5 1 37
SURVIVAL_RATE (%) : (OBSERVED FATES SHOWN IN PARENTHESES)
ALL STAGES
1 - YEAR 22 (21) 30 (2 3) 24
3- YEAR 8 ( 6) 12 (10)
5- YEAR 5 ( !!) 1 0 ( 7)
IOC ALIZED
1- YEAR l; 8 (1,5) 55% (51*) xx;
3- YEAR 21 (18) 23+ (19*)
5 - YEAR 16 (11) 19% (1 4*)
REGIONAL. -
1 - YEAR 22 (21) 27 (26) 29 ×
3- YEAR 5 ( l;) 10 ( 9)
5 - YEAR 3 ( 2) 7 ( 5)
DIST ANT -
1- YEAR {} ( !) 1 iſ (13) 3
3- YEAR 1 ( 1) 6 ( 5)
5- YEAR 0 ( 0) 5 ( !!)
* RATES HAV E A S TANDARD ERKO R BETWEEN 5 AND 1 0 PE RCENT.
(23)
(**)
(28%)
( 3)
1960-64
7 12
2 l;
3 l;
39
3
38
2
1
l,
O
O
55
21 (20)
12 (10)
9 ( 7)
55 (52)
39 (34)
30 (24)
17 (17)
6 ('5)
l, ( 3)
l! ( !)
O ( 0)
O ( 0)
FEMALE
1965-69
6l. 5
22
32
l! 2,
l;
38
2
2
7
2
1
l, 7
23 (22)
11 ( 9)
7 ( 6)
55 (52)
3 l; (30)
27 (21)
22 (21)
7 ( 7)
l; ( 3)
7 ( 7)
1 ( 1)
O ( 0)
25 (24)
l, 3% (41*)
324 (30+)
8 ( 8)
PANCREAS: STAGE AND TREATMENT DISTRIBUTIONS, RELATIVE SURVIVAL RATES
NUMBER OF CASES
PERCENT_CLASSIFIED_AS:
LOCALIZ ED
REGIONAL
DISTANT
UNKNOWN
PERCENT_TREATED BY:
SURGERY ONLY
R ADI ATION ONLY
CHEMO/HORM ONLY
RAD+CHEMO/HORM
NONE
Jºº smº
1
i
7
SUFWIWAL_RATE (%) : (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES
1- YEAR
3- YEAR
5 - YEAR
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIONAL
1- YEAR
3- YEAR
5 - YEAR
DIST ANT
1- YEAR
3- YEAR
5- YEAR
:
( 9)
( 2)
( 1)
(24)
( 7)
( 5)
(12)
( 1)
( 1)
( lā)
( 1)
( 0)
10
2
1
:
(10)
( 2)
( 1)
(23)
( 7)
( !)
(16)
( 2)
( 1)
( 5)
( 1)
( 0)
1970-71 1960-64
553 1 165
13 17
15 23
6 l; 53
8 7
1 O 7
2 3
19 8
3 2
65 80
1 l; (13) 10 (10)
2 ( 2)
2 ( 1)
33-k (31#) 20 (19)
li ( 3)
3 ( 3)
25 (24) 16 (16)
5 ( !!)
3 ( 3)
6 ( 5) 5 ( 5)
* RATES HAWE A STANDARD ERROR BETWEEN 5 AND 1 0 PERCENT.
( 1)
( 0)
* * * * * ºr ºs emº ºm º º sº º ºs. ººmma tº º
1965-69
4.21
:::
:
gººmºsº
1229
(12)
( 3)
( 2)
(28)
( 3)
( 3)
(18)
( 5)
( !)
( 7)
( 2)
( 1)
1970-71
15
30+
30 x
l, 91
16
63
18
70
(15)
(28+)
(29*)
( 8)
CANCER OF RESPIRATORY SYSTEM
| , ， \，\！

§
NUMBER OF CAS ES
LOCALIZED
REGIONAL
DIST ANT
UNKNOWN
PERCENT_TREATED_BX:
SURGERY ONLY
RADIATION ONLY
SURG +RAD ONLY
CHEMO/HORM ONLY
RAD+CHEMO/HORM
SUR G+RAD+C HEMO/HORM
NONE
—SURVIVAL RATB (#) :
ALL STAGES
1 - YEAR
3- YEAR
5- YEAR .
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIONAL
1- YEAR
3- YEAR
5- YEAR
DIST ANT
1 - YEAR
3- YEAR
5- YEAR
- NOSE, NASAL CAVITIES, AND MIDDLE EAR:
STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
* * * * * *
69
l; 6
l! 3
8 l;
6 l; +
6.3%
62
37
33
l, lººk
15+
16+
(66)
(l;0)
(35)
(80)
(57+.)
(51#)
(59)
(33)
(27)
(43*)
(13+)
(13+)
(OBSERVED RATES SHOWN
68
43
35
89
69*
60+
69
l; 1
33
l; 0 +
17+
1 1 +
285
(65)
(38)
(29)
(86)
(6.1#)
(48*)
(66)
(37)
(27)
(38%)
(15+)
( 8+)
1970-71
**--
122
IN PARENTHESES)
65 (62)
87+ (81.4)
61 + (59%)
xx; (**)
* RATES HAVE A STANDARD ERROR BETWEEN 5 AND 1 0 PERCENT .
** NUMBER OF CAS ES TOO SMALL TO YIELD RELIABLE RATES,
1960-64
217
39
l; 7
9
5
22
39
28
1
2
3 º
l;
69 (67)
l, 5 (41)
39 (3 l;)
75 (73)
65% (60*)
57+ (1,94.)
68 (67)
33% (30+)
28% (25*)
sk ºr (**)
:: 2& (**)
sk x): (**)
OR STANDARD ERROR
GREATER THAN 10
FEMALE
1965-69
215
38
(; 1
17
l!
21
30
36
1
5
2
l;
78 (76)
53 (1.8)
l, 8 (l, 1)
9 1 (89)
77+ (714)
73+ (64+)
70* (68*)
1, 2* (38+)
38% (32*)
59% (58+)
24+ (23%)
14+ (13+)
PER CENT •
76*
86*
× 2k
(74 +)
(**)
(84*)
(**)
LARYNX: STAGE AND TREATMENT DISTRIBUTIONS, RELATIVE survival RATES
MALE FEMALE
1960-64 1965–69 1970-71 1960-61; 1965-69 1970-71
NUMBER OF CAS ES 2262 231 iſ 911 261 350 126
PERCENT_CLASSIFIED_AS:
LOCALIZ ED 60 & 1 57 57 57 50
REGIONAL 33 31 30 35 36 37
DISTANT l! 7 10 5 l! 10
UNKNOWN 3 1 3 3 3 3
PERCENT_TEEATED_B.Y.: -
SURGERY ONLY t; 1 3 l; 29 36 3 l; 32
RADIATION ONLY 38 l; 1 l, 7 l; 1 l; 1 l;0
SUR G + RAD ONLY 11 16 17 12 16 21
R AD+CHEMO/HORM 1 2 1 2 2 3
SURG+RAD+c HEMO/HORM 1 1 1 O 3 2
NONE 7 5 5 8 t; 2
_SURVIVAL_RATE (%) : (OBSERVED RATES SHOWN IN PARENTHESES)
ALL STAGES +
1- YEAR 79 (77) 84 (81) 83 (80) 79 (77) 87 (86) 84 (82)
3- YEAR 61 (55) 68 (61) 59 (56) 70 (66)
5- YEAR - 54 (t; 5) 62 (51) 52 (1,6) 59 (53)
LOCALIZED - \
1- YEAR 91 (88) 94 (90) 93 (90) 88 (86) 96 (94) 92 (91)
3- YEAR 79 (70) 85 (75) 73 (69) 83 (78)
5 - YEAR 72 (59) 80 (65) 67 (60) 73 (66)
REGIONAL
1 - YEAR 64 (62) 74 (7.2) 79 (76) 73 (72) 81 (79) 78% (77+.)
3- YEAR 38 (34) 48 (4.3) l, 6% (44*) 54 (51)
5 - YEAR - 30 (25) 38 (32) 33+ (30+) l, 04 (36+)
DIST ANT - - f
1- YEAR t; 3% (41*) 51 (50) 51* (49*) * * (**) ** (**) ** (**)
3- YEAR 17+ (15+) 21 (19) * * (**) × 3k (**)
5- YEAR 13+ (10+) 17 (14) * * (**) ** (**)
*RATES HAVE A STANDARD ERROR BETWEEN
** NUMBER OF CAS ES TOO SMALL TO YIELD RELIABLE RATES,
5 AND 1 0 PERCENT .
OR STANDARD ERROR GREATER THAN 10 PERCENT.
3
§
LUNG & BRONCHUS: STAGE AND TREATMENT DISTRIBUTIONS: RELATIVE SURVIVAL RATES
º º |
{ -
*-* -º ſº º ºs wºme ºn ºn tº º ºs º º me tº º *A**--------------- -----EBHARB--------------
1960-64 1965:69 1970-71 1960-65. 1965-69 1970-71
NUMBER OF CASES 10560 12373 l, 876 1965 2937 1 l; 15
PERCENT_CLASSIFIED_AS: -
LOCALIZED 19 18 17 19 17 17
REGIONAL 33 24 21, 30 23 21
DIST ANT 38 l, 7 l; 8 l! 2 5 1 51
UNKNOWN 10 11 11 9 9 11
PERCENT_TREATED_B.Y.:
SURGERY ONLY 17 17 17 21 20 21
RAD IATION ONLY 30 36 I () 21, 33 31
SUR G+RAD ONLY 5 7 6 5 8 6
CHEMO/HORM ONLY 8 6 9 8 9
SURG+CHEMO/HORM 2 1 1 2 1 1
RAD+CHEMO/HORM 10 7 8 10 7 11
SURG+ RAD+CHEMO/HORM 1 1 1 1 1 1
NONE 27 25 21 28 22 20
SURVIVAL_RATE (%).: (OBSERVED RATES SHOWN IN PAREN THESES)
ALL STAGES
1 - YEAR 25 (24) 26 (25) 28 (27) 30 (29) 33 (32) 33 (33)
3- YEAR 10 ( 9) 10 ( 9) 15 (14) 16 (15)
5- YEAR 8 ( 7) 8 ( 7) 12 (10) 12 (11)
LOCALIZED - -
1 - YEAR 53 (51) 56 (53) 60 (58) 69 (67) 73 (72) 7 1 (70)
3- YEAR 32 (28) 36 (31) 50 (l, 6) 53 (50)
5- YEAR 27 (22) 29 (23) l! 2 (37) l; 8 (l, 3)
REGIONAL " *
1 - YEAR 28 (28) 36 (35) l! 0 (39) 36 (36) l, 7 (l; 6) 5 O (l;9)
3- YEAR 10 ( 9) 12 (11) 1 l; (13) 20 (19)
5- YEAR 7 ( 6) 9 ( 7) 9 ( 8) 13 (12)
DIST ANT
1- YEAR 8 ( 7) 1 0 (10) 12 (11) 1 O (10) 1 3 (13) 16 (15)
3- YEAR 1 ( 1) 2 ( 1) 1 ( 1) 3 ( 3)
5- YEAR 1 ( 0) 1 ( 1) 1 ( 1) 1 ( 1)
CANCER OF FEMALE REPRODUCTIVE SYSTEM
ſ „uſ （)(（）)


FEMALE BREAST: STAGE AND TREATMENT DISTRIBUTIONS:
RELATIVE SURVIVAL RATES
––––EBHALE
Jº .mº.gº.
NUMBER OF CAS ES
PERCENT_CLASSIFIED_AS:
LOCALIZED
REGIONAL
DISTANT
UNKNOWN
PERCENT_TREATED_BY:
SURGERY ON LY
R A DIATION ONLY
SUR G + RAD ONLY
CHEMO/HORM ONLY
SURG+CHEMO/HORM
RAD+CHEMO/HORM
SURG+RAD+C HEMO/HORM
NCNE
_SURVIVAL_RATE (%).
AL L STAGES
1 - YEAR
3- YEAR
5 - YEAR
LOCALIZED
1 - YEAR
3- YEAR
5- YEAR
REGIONAL
1 - YEAR
3- YEAR
5 - YEAR
DIST ANT
1 - YEAR
3- YEAR
5- YEAR
88
72
62
97
91
8 l;
91
66
52
l; 0
1 3
7
.
|
(86)
(67)
(5 l;)
(95)
(84)
(73)
(89)
(6.2)
(l;7)
(39)
(12)
( 6)
36
_º -ºº ºr ºme
1965–69
14493
89
7 l;
6 tº
37
9 1
8 ||
92
70
56
i{5
1 7
1 0
l; 7
l; 1
1 0
25
3
(87)
(6 8)
(56)
(95)
(84)
(73)
(90)
(65)
(5.0)
(là (1)
(16)
( 9)
(OBSERVED RATES SHOWN IN PARENTHESES)
90
99'
93
l, 7
1970-71
5600
i
(88)
(96)
(91)
(46)
UNIVERSITY OF MICHIGAN
|||||||||||||||||||
ģŐi 5 OO379 7720
[][] N[] I REMOWE
[]|R
MUTILAȚIE CARD
DHEW Publication No. (NIH) 75-767